

CONTENTS

Introduction	1
<i>K. Miller</i>	
In order to develop effective new therapies for HRPC, it is vital to examine the current therapeutic landscape and identify unmet needs of patients and physicians. A satellite symposium was held to examine these issues and discuss emerging therapeutic approaches.	
<hr/>	
Highlighting Unmet Needs: Real Patients, Difficult Choices	4
<i>M. Maffezzini</i>	
The current treatment landscape for hormone-resistant prostate cancer is not ideal. Those treatments that are available are limited by lack of data, by suboptimal efficacy, and often by significant toxicity. Consequently, there is a requirement for new, safe, efficacious therapies.	
<hr/>	
Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer	13
<i>D.W.W. Newling</i>	
Demand for new cancer drugs requires a reduction in the length of clinical trials. Measurement of prostate-specific antigen as a surrogate end point to overall survival has been investigated, but data are equivocal, particularly regarding novel targeted agents.	
<hr/>	
Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer	20
<i>J.B. Nelson</i>	
Preclinical studies of endothelin-1 (ET-1), endothelin A (ET _A) receptor, and endothelin B (ET _B) receptor indicate an important role in prostate cancer (PCa) progression, particularly at sites of skeletal metastases. Clinical trials of ET _A receptor antagonists in castration-resistant prostate cancer (CRPC) support ongoing investigations of these agents.	
<hr/>	
The Specific Endothelin A Receptor Antagonist ZD4054: Preclinical and Clinical Results	29
<i>N.D. James, J.W. Growcott</i>	
The specific endothelin A receptor antagonist ZD4054 has been associated with a promising improvement in overall survival compared with placebo and was generally well tolerated in patients with metastatic hormone-resistant prostate cancer who were pain free or mildly symptomatic.	
<hr/>	
Challenges and Opportunities in Hormone-Resistant Prostate Cancer	36
<i>K. Miller</i>	
The limited treatment options for hormone-resistant prostate cancer present many challenges. New approaches include docetaxel combinations with novel agents, immunotherapeutics, and endothelin A (ET _A) receptor antagonism. Several clinical trials are currently underway, including a phase 3 programme investigating the specific ET _A receptor antagonist ZD4054.	
<hr/>	

